Bayer Reports Progress in Clinical Program for Riociguat
- Details
- Category: Bayer
Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase (sGC) stimulators.
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has signed a licence agreement with Evec, Inc., Japan, for one of its fully-human therapeutic antibody programmes. Based on the agreement, Boehringer Ingelheim will obtain worldwide exclusive development and commercialisation rights for the complete programme.
Roche invests 215 million Swiss francs in diagnostics facility at Penzberg
- Details
- Category: Roche
Roche is investing 215 million Swiss francs (136 million euros) in research, development and production at its site in Penzberg, near Munich. The money will be used to construct a multi-purpose building for Roche Diagnostics.
Shire Limited has changed its name to Shire plc
- Details
- Category: Shire
Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the approval by shareholders at the Annual General Meeting on September 24, 2008, the Company has changed its name to Shire plc with effect from today.
Bayer starts new research cooperation in Asia
- Details
- Category: Bayer
Bayer Schering Pharma and the National University of Singapore (NUS) have agreed to cooperate in the field of pre-clinical cancer research. The initial collaboration with the NUS will focus on three joint projects in the field of oncology.
Data from one-year liraglutide phase 3 study published in The Lancet
- Details
- Category: Novo Nordisk
Data from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug.
US Court Denies Teva's Motion For Summary Judgment In Pulmicort Respules Patent Litigation
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation suspension) patent litigation.
More Pharma News ...
- Nycomed optimises its European manufacturing network
- Pfizer Launches New Medicine Safety Website for Healthcare Professionals and Patients
- Novo Nordisk acquires intellectual property rights from Neose Technologies
- Bayer HealthCare acquires German DIREVO Biotech AG
- DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry
- Bayer Intensifies Research in Early Diagnosis of Alzheimer's Disease
- Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial